Physician profile
Michael B Hall
NPI 1396002606
$920.63
in general payments reported to CMS, 2019-2025
21 companies · $91.57 in 2025
The $91.57 reported for 2025 was less than what a typical Otolaryngology/Facial Plastic Surgery provider received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $253 · 2020: $21.19 · 2021: $204 · 2022: $74.15 · 2023: $72.34 · 2024: $205 · 2025: $91.57.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $368.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $368.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $135.66 | 2019-2021 | |
| Genentech USA, INC. | $112.45 | 2019-2020 | |
| Amgen INC. | $90.22 | 2019 | |
| Glaxosmithkline, LLC. | $77.00 | 2022-2024 | Nucala |
| Kerecis Limited | $59.99 | 2024-2025 | Kerecis Surgiclose, Kerecis Omega3 Marigen, Kerecis Graftguide |
| Lemaitre Vascular, INC. | $52.52 | 2024 | Artegraft Vascular Graft |
| Optinose US, INC. | $43.97 | 2024 | |
| Lilly USA, LLC | $40.68 | 2021-2022 | |
| Genzyme Corporation | $38.60 | 2021-2024 | |
| Sun Pharmaceutical Industries INC. | $36.91 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $32.94 | 2021 | |
| Becton, Dickinson and Company | $29.98 | 2024 | Arista Ah Flexitip |
| Janssen Biotech, INC. | $28.84 | 2025 | Tremfya, Stelara, Simponi Aria |
| Biofrontera INC. | $24.58 | 2019 | |
| Medtronic, INC. | $24.31 | 2023 | Ligasure |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $19.76 | 2019 | |
| Almirall LLC | $16.87 | 2021 | |
| Pierre Fabre Pharmaceuticals, INC. | $14.82 | 2019 | |
| Leo Pharma INC. | $14.40 | 2025 | Adbry |
| Revance Therapeutics, INC. | $14.11 | 2024 | Daxxify |
| Organon LLC | $12.02 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.